Last reviewed · How we verify
ODM-108 Part III
ODM-108 mechanism of action is not publicly disclosed; Phase 1 evaluation focused on safety and pharmacokinetics in healthy volunteers.
ODM-108 is a small-molecule investigational drug developed by Orion Corporation (Orion Pharma) that was discontinued during early clinical development. The compound, with a molecular weight of 529.67 Da, was evaluated in Phase 1 trials for safety, tolerability, and pharmacokinetic/pharmacodynamic effects in healthy volunteers, but the program did not advance to later-stage development. No FDA approval was obtained, and the drug never reached marketed status. The discontinuation suggests either unfavorable safety/tolerability findings, lack of differentiation versus existing therapies, or strategic portfolio reprioritization by Orion. Without published clinical data or regulatory filings, ODM-108 remains a failed early-stage asset with no commercial significance or ongoing development.
At a glance
| Generic name | ODM-108 Part III |
|---|---|
| Sponsor | Orion Corporation, Orion Pharma |
| Drug class | Unknown — investigational small molecule |
| Target | Not publicly disclosed |
| Modality | Small molecule |
| Therapeutic area | Metabolic |
| Phase | discontinued |
Mechanism of action
ODM-108 was an investigational small-molecule compound developed by Orion Corporation that entered Phase 1 clinical testing to assess basic safety, tolerability, and how the body processes the drug (pharmacokinetics) and how the drug affects the body (pharmacodynamics). The trial enrolled 85 healthy male volunteers but was terminated before completion, suggesting either safety concerns, lack of efficacy signals, or strategic discontinuation. Without published data or regulatory filings, the specific molecular target, binding mechanism, and intended therapeutic indication remain undisclosed in the public domain.
Approved indications
Pipeline indications
- Indication under Phase 1 evaluation (not specified) — Phase 1
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ODM-108 Part III CI brief — competitive landscape report
- ODM-108 Part III updates RSS · CI watch RSS
- Orion Corporation, Orion Pharma portfolio CI